{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:50:17Z","timestamp":1781034617899,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd002109.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T00:00:00Z","timestamp":1412812800000}}],"reference-count":157,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002109.pub4","type":"journal-article","created":{"date-parts":[[2014,10,10]],"date-time":"2014-10-10T07:31:41Z","timestamp":1412926301000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Antibiotics for community-acquired pneumonia in adult outpatients"],"prefix":"10.1002","volume":"2014","author":[{"given":"Smita","family":"Pakhale","sequence":"first","affiliation":[{"name":"The Ottawa Hospital, Ottawa Hospital Research Institute and the University of Ottawa; Department of Medicine; 501 Smyth Road Ottawa ON Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunita","family":"Mulpuru","sequence":"additional","affiliation":[{"name":"The Ottawa Hospital, General Campus; Division of Respirology; 501 Smyth Road Box 211 Ottawa ON Canada K1H 8L6"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo JM","family":"Verheij","sequence":"additional","affiliation":[{"name":"University Medical Center Utrecht; Julius Center for Health Sciences and Primary Care; PO Box 85500 Utrecht Netherlands 3508 GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M","family":"Kochen","sequence":"additional","affiliation":[{"name":"University of G\u00f6ttingen Medical School; Department of General Practice\/Family Medicine; Ludwigstrasse 37 Freiburg Germany D-79104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gernot GU","family":"Rohde","sequence":"additional","affiliation":[{"name":"Maastricht University Medical Center; Department of Respiratory Medicine; PO box 5800 Maastricht Netherlands 6202 AZ"},{"name":"CAPNETZ STIFTUNG; Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise M","family":"Bjerre","sequence":"additional","affiliation":[{"name":"University of Ottawa; Department of Family Medicine, Bruyere Research Institute; 43 Bruyere St Room 369Y Ottawa ON Canada K1N 5C8"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,10,9]]},"reference":[{"issue":"Suppl A","key":"10.1002\/14651858.CD002109.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/jac\/27.suppl_A.117","article-title":"A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community-acquired pneumonia","volume":"27","author":"Anderson","year":"1997","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.103.3.697","article-title":"Treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing clarithromycin with erythromycin","volume":"103","author":"Chien","year":"1993","journal-title":"Chest"},{"issue":"10","key":"10.1002\/14651858.CD002109.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.49.10.4035-4041.2005","article-title":"Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired pneumonia in adults","volume":"49","author":"D'Ignazio","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0004|cit4","first-page":"2230","article-title":"Single-dose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community-acquired pneumonia in adults","volume":"4","author":"Drehobl","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1128\/AAC.05596-11","article-title":"Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies","volume":"56","author":"English","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002109.pub4-BIB0007|cit7","first-page":"255","article-title":"Clinical evaluation of telithromycin for community-acquired pneumonia - phase III double-blind comparative study of telithromycin versus levofloxacin [Japanese]","volume":"51","author":"Kohno","year":"2003","journal-title":"Japanese Journal of Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0149-2918(04)90005-7","article-title":"Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults","volume":"26","author":"Mathers Dunbar","year":"2004","journal-title":"Clinical Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD002109.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1128\/AAC.00197-13","article-title":"Randomized, double-blind, multicentre phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia","volume":"57","author":"Oldach","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0010|cit10","first-page":"156","article-title":"Antibiotic therapy in pneumonia: a comparative study of oral antibiotics in a rural healthcare centre","volume":"3","author":"Udupa","year":"2011","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"},{"issue":"2-3","key":"10.1002\/14651858.CD002109.pub4-BIB0011|cit11","first-page":"31","article-title":"Community-acquired acute pneumonias in the adult. Controlled therapeutic study. Uruguay","volume":"XXXII","author":"Vacarezza","year":"2010","journal-title":"Archivos de Medicina Interna"},{"issue":"10","key":"10.1002\/14651858.CD002109.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.00295-10","article-title":"Efficacy and safety of nemonoxacin versus levofloxacin for community acquired pneumonia","volume":"54","author":"Rensburg","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"10","key":"10.1002\/14651858.CD002109.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1128\/AAC.00295-10","article-title":"Efficacy and safety of nemonoxacin versus levofloxacin for community acquired pneumonia","volume":"54","author":"Rensburg","year":"2010","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0014|cit14","first-page":"213","volume":"6","author":"Alcacer","year":"1993","journal-title":"Revista Espa\u00f1ola de Quimioterapia"},{"issue":"Suppl","key":"10.1002\/14651858.CD002109.pub4-BIB0015|cit15","first-page":"S142","article-title":"P319 Multicenter, comparative study of levofloxacin high-dose, IV oral sequential therapy for CAP with moxifloxacin in Indonesia","volume":"42","author":"Arifin","year":"2013","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"6","key":"10.1002\/14651858.CD002109.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3760\/cma.j.issn.0366-6999.20131778","article-title":"Ertapenem versus ceftriaxone for the treatment of complicated infections: a meta-analysis of randomized controlled trials","volume":"127","author":"Bai","year":"2014","journal-title":"Chinese Medical Journal"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1742-1241.1999.tb11740.x","article-title":"Efficacy of twice-daily amoxycillin\/clavulanate in lower respiratory tract infections","volume":"53","author":"Balgos","year":"1999","journal-title":"International Journal of Clinical Practice"},{"issue":"10","key":"10.1002\/14651858.CD002109.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/BF02111352","article-title":"Efficacy and safety of cefprozil versus other beta-lactam antibiotics in the treatment of lower respiratory tract infections","volume":"13","author":"Ball","year":"1994","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/BF01968024","article-title":"Comparative study of azithromycin and amoxicillin\/clavulanic acid in the treatment of lower respiratory tract infections","volume":"10","author":"Balmes","year":"1991","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"Suppl 4A","key":"10.1002\/14651858.CD002109.pub4-BIB0020|cit20","first-page":"208","article-title":"Low-dose ciprofloxacin in respiratory tract infections: a randomized comparison with doxycycline in general practice","volume":"82","author":"Bantz","year":"1987","journal-title":"American Journal of Medicine"},{"issue":"Suppl B","key":"10.1002\/14651858.CD002109.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/jac\/22.Supplement_B.155","article-title":"Comparison of spiramycin and doxycycline in the treatment of lower respiratory infections in general practice","volume":"22","author":"Biermann","year":"1988","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/TCRM.S41131","article-title":"Cefditoren versus levofloxacin in patients with exacerbations of chronic bronchitis: serum inflammatory biomarkers, clinical efficacy, and microbiological eradication","volume":"9","author":"Blasi","year":"2013","journal-title":"Journal of Therapeutics and Clinical Risk Management"},{"issue":"7","key":"10.1002\/14651858.CD002109.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0009922806291016","article-title":"Comparative tolerability, safety and efficacy of tablet formulations of twice-daily clarithromycin 250 mg versus once-daily extended-release clarithromycin 500 mg in pediatric and adolescent patients","volume":"45","author":"Block","year":"2006","journal-title":"Clinical Pediatrics"},{"issue":"8","key":"10.1002\/14651858.CD002109.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2165\/00044011-200323080-00001","article-title":"Comparison of clarithromycin and amoxicillin\/clavulanic acid for community-acquired pneumonia in an era of drug-resistant streptococcus pneumoniae","volume":"23","author":"Bonvehi","year":"2003","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14656566.2012.656090","article-title":"Tobramycin for the treatment of bacterial pneumonia in children","volume":"13","author":"Bothra","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1741-7015-9-44","article-title":"Access to a polymerase chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics: a randomised, controlled trial","volume":"9","author":"Brittain-Long","year":"2011","journal-title":"BMC Medicine"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/j.1469-0691.1999.tb00705.x","article-title":"Comparative study of levofloxacin and amoxycillin\/clavulanic acid in adults with mild-to-moderate community-acquired pneumonia","volume":"5","author":"Carbon","year":"1999","journal-title":"Clinical Microbiology and Infection"},{"issue":"8","key":"10.1002\/14651858.CD002109.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1517\/14656566.2012.685718","article-title":"Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection","volume":"13","author":"Casapao","year":"2012","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1378\/chest.100.6.1497","article-title":"Temafloxacin compared with ciprofloxacin in mild to moderate lower respiratory tract infections in ambulatory patients","volume":"100","author":"Chodosh","year":"1991","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0030|cit30","first-page":"A5481","article-title":"Microbiological outcomes of 2 multicenter phase 3 clinical trials of ceftaroline in community-acquired bacterial pneumonia","volume":"181","author":"Critchley","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002109.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2165\/00003495-199958002-00108","article-title":"Oral trovafloxacin compared with amoxicillin (plus optional erythromycin) for the treatment of mild to moderate community-acquired pneumonia","volume":"58","author":"Daniel","year":"1999","journal-title":"Drugs"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002109.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.2165\/00003495-199958002-00102","article-title":"Trovafloxacin vs high dose amoxicillin in the treatment of community-acquired bacterial pneumonia","volume":"58","author":"Daniel","year":"1999","journal-title":"Drugs"},{"issue":"Suppl 3A","key":"10.1002\/14651858.CD002109.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0002-9343(91)90399-I","article-title":"Multicenter evaluation of azithromycin and cefaclor in acute lower respiratory tract infections","volume":"91","author":"Dark","year":"1991","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/1874306401307010013","article-title":"Tigecycline versus levofloxacin in hospitalized patients with community-acquired pneumonia: an analysis of risk factors","volume":"7","author":"Dartois","year":"2013","journal-title":"Open Respiratory Medicine Journal"},{"issue":"Suppl","key":"10.1002\/14651858.CD002109.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0732-8893(92)90133-E","article-title":"Comparison of two oral antibiotics, roxithromycin and amoxicillin plus clavulanic acid, in lower respiratory tract infections","volume":"15","author":"Dautzenberg","year":"1992","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1128\/AAC.50.4.1164-1169.2006","article-title":"Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care","volume":"50","author":"Dean","year":"2006","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl B","key":"10.1002\/14651858.CD002109.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/jac\/22.Supplement_B.159","article-title":"Comparison of spiramycin with erythromycin for lower respiratory tract infections","volume":"22","author":"Cock","year":"1988","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0149-2918(97)80047-1","article-title":"Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study","volume":"19","author":"Donowitz","year":"1997","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD002109.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/jac\/dks277","article-title":"Considerations of antibiotic therapy duration in community and hospital-acquired bacterial infections","volume":"67","author":"Esposito","year":"2012","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD002109.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"A multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/48.1.67","article-title":"Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin","volume":"48","author":"File","year":"2001","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD002109.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1128\/AAC.48.9.3323-3331.2004","article-title":"Double-blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced-amoxicillin clavulanate (2,000\/125 milligrams) versus those of amoxicillin-clavulanate (875\/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community-acquired pneumonia in adults","volume":"48","author":"File","year":"2004","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"55","key":"10.1002\/14651858.CD002109.pub4-BIB0043|cit43","first-page":"133","article-title":"Assessment of outcomes at an entry time point may identify a differential effect of macrolide therapy on community-acquired pneumonia due to atypical pathogens","volume":"18","author":"File Jr","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002109.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/cis559","article-title":"Summary of ceftaroline fosamil clinical trial studies and clinical safety","volume":"55","author":"File Jr","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0045|cit45","first-page":"748","article-title":"Efficacy and safety of moxifloxacin vs clarithromycin for community-acquired pneumonia","volume":"16","author":"Fogarty","year":"1999","journal-title":"Infections in Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002109.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0149-2918(02)80084-4","article-title":"A comparison of cefditoren pivoxil and amoxicillin\/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel-group study","volume":"24","author":"Fogarty","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002109.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/378406","article-title":"Multicenter, open-label, randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults","volume":"38","author":"Fogarty","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0048|cit48","first-page":"131","article-title":"Clarithromycin versus cefaclor in lower respiratory tract infections","volume":"18","author":"Fong","year":"1995","journal-title":"Clinical and Investigative Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s10156-012-0514-4","article-title":"Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial","volume":"19","author":"Fujita","year":"2013","journal-title":"Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy)"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0050|cit50","first-page":"185","article-title":"Bacterial infections in the elderly patient: focus on sitafloxacin","volume":"4","author":"Ghebremedhin","year":"2012","journal-title":"Clinical Medicine Insights: Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/S0149-2918(02)85148-7","article-title":"A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia","volume":"24","author":"Gotfried","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"Suppl C","key":"10.1002\/14651858.CD002109.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/jac\/37.suppl_C.93","article-title":"Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study","volume":"37","author":"Gris","year":"1996","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD002109.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s15010-002-2096-z","article-title":"Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia","volume":"30","author":"Hagberg","year":"2002","journal-title":"Infection"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/jac\/37.3.555","article-title":"Comparison of oral cefuroxime axetil and oral amoxycillin\/clavulanate in the treatment of community-acquired pneumonia","volume":"37","author":"Higuera","year":"1996","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"7","key":"10.1002\/14651858.CD002109.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1053\/rmed.2001.1113","article-title":"The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia","volume":"95","author":"Hoeffken","year":"2001","journal-title":"Respiratory Medicine"},{"issue":"Suppl E","key":"10.1002\/14651858.CD002109.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/jac\/31.suppl_E.147","article-title":"A single-blind comparison of three-day azithromycin and ten-day co-amoxiclav treatment of acute lower respiratory tract infections","volume":"31","author":"Hoepelman","year":"1993","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0924-8579(97)00043-5","article-title":"A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome","volume":"9","author":"Hoepelman","year":"1998","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0732-8893(91)90097-Y","article-title":"Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections","volume":"14","author":"Kammer","year":"1991","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0059|cit59","first-page":"841","article-title":"Comparison of once-daily and twice-daily cefixime regimens with amoxicillin in the treatment of acute lower respiratory tract infections","volume":"48","author":"Kiani","year":"1990","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"10","key":"10.1002\/14651858.CD002109.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/BF01975846","article-title":"Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia","volume":"10","author":"Kinasewitz","year":"1991","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"6","key":"10.1002\/14651858.CD002109.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s10156-013-0618-5","article-title":"Early switch therapy from intravenous sulbactam\/ampicillin to oral garenoxacin in patients with community-acquired pneumonia: a multicenter, randomized study in Japan","volume":"19","author":"Kohno","year":"2013","journal-title":"Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy)"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0062|cit62","first-page":"26","article-title":"A comparison of oral therapy with clindamycin and penicillin G in common gram-positive infections","volume":"14","author":"Lacny","year":"1972","journal-title":"Current Therapeutic Research"},{"issue":"65","key":"10.1002\/14651858.CD002109.pub4-BIB0063|cit63","first-page":"137","article-title":"Intravenous azithromycin - single dose 1.5 g vs. 500 mg once daily for 3 days in patients with community-acquired pneumonia: a prospective and randomized study","volume":"18","author":"Lagler","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"issue":"Suppl C","key":"10.1002\/14651858.CD002109.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/jac\/37.suppl_C.115","article-title":"Efficacy, safety and tolerability of azithromycin versus roxithromycin in the treatment of acute lower respiratory tract infections","volume":"37","author":"Laurent","year":"1996","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"9","key":"10.1002\/14651858.CD002109.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/BF03261911","article-title":"High-dose levofloxacin in community-acquired pneumonia: a randomized, open-label study","volume":"32","author":"Lee","year":"2012","journal-title":"Clinical Drug Investigation"},{"issue":"8","key":"10.1002\/14651858.CD002109.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.rmed.2004.04.007","article-title":"Gemifloxacin once daily for 7 days compared to amoxicillin\/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin","volume":"98","author":"L\u00e9ophonte","year":"2004","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0067|cit67","first-page":"131","article-title":"A comparative study of dirithromycin and erythromycin in bacterial pneumonia","volume":"28","author":"Liippo","year":"1994","journal-title":"Journal of Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1473-3099(12)70300-6","article-title":"Amoxicillin for acute lower-respiratory-tract infection in primary care when pneumonia is not suspected: a 12-country, randomised, placebo-controlled trial","volume":"13","author":"Little","year":"2013","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1183\/09031936.95.08121999","article-title":"Treatment of community-acquired pneumonia: a randomized comparison of sparfloxacin, amoxycillin-clavulanic acid and erythromycin","volume":"8","author":"Lode","year":"1995","journal-title":"European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1469-0691.1998.tb00376.x","article-title":"Sparfloxacin as alternative treatment to standard therapy for community-acquired bacteremic pneumococcal pneumonia","volume":"4","author":"Lode","year":"1998","journal-title":"Clinical Microbiology and Infection"},{"issue":"6","key":"10.1002\/14651858.CD002109.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1469-0691.2004.00875.x","article-title":"Once-daily oral gatifloxacin vs three-times-daily co-amoxiclav in the treatment of patients with community-acquired pneumonia","volume":"10","author":"Lode","year":"2004","journal-title":"Clinical Microbiology and Infection"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1469-0691.2004.0906.x","article-title":"A randomised, double-blind, double-dummy comparative study of gatifloxacin with clarithromycin in the treatment of community-acquired pneumonia","volume":"10","author":"Lode","year":"2004","journal-title":"Clinical Microbiology and Infection"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1440-1843.2011.01978.x","article-title":"Procalcitonin guidance for reduction of antibiotic use in low-risk outpatients with community-acquired pneumonia","volume":"16","author":"Long","year":"2011","journal-title":"Respirology"},{"issue":"587","key":"10.1002\/14651858.CD002109.pub4-BIB0074|cit74","first-page":"594","volume":"29","author":"L\u00f3pez-V\u00e9jar","year":"2013","journal-title":"Medicina Interna de M\u00e9xico"},{"issue":"407","key":"10.1002\/14651858.CD002109.pub4-BIB0075|cit75","first-page":"357","article-title":"Comparison of amoxycillin and clarithromycin as initial treatment of community-acquired lower respiratory tract infections","volume":"46","author":"MacFarlane","year":"1996","journal-title":"British Journal of General Practice"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.medmal.2012.12.005","article-title":"How to reduce antibiotic consumption for community-acquired pneumonia","volume":"43","author":"Montassier","year":"2013","journal-title":"Medicines et Maladies Infectieuses"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1378\/chest.116.4.974","article-title":"A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia","volume":"116","author":"Moola","year":"1999","journal-title":"Chest"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/BF01704619","article-title":"Comparison of loracarbef (LY 163892) versus amoxicillin in the treatment of bronchopneumonia and lobar pneumonia","volume":"20","author":"M\u00fcller","year":"1992","journal-title":"Infection"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1128\/AAC.01779-12","article-title":"Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor","volume":"57","author":"Naderer","year":"2013","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/jac\/39.4.499","article-title":"Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline","volume":"39","author":"The Nordic Atypical Pneumonia Study Group","year":"1997","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0082|cit82","first-page":"97","article-title":"Not available","volume":"3","author":"Navarta","year":"2010","journal-title":"Revista Americana de Medicina Respiratoria"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1378\/chest.104.5.1393","article-title":"Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections","volume":"104","author":"Neu","year":"1993","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.idc.2012.11.008","article-title":"What is the role of antimicrobial stewardship in improving outcomes of patients with CAP","volume":"27","author":"Nussenblatt","year":"2013","journal-title":"Infectious Disease Clinics of North America"},{"issue":"Suppl A","key":"10.1002\/14651858.CD002109.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/40.suppl_1.73","article-title":"Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia","volume":"40","author":"O'Doherty","year":"1997","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s100960050201","article-title":"Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia","volume":"17","author":"O'Doherty","year":"1998","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1378\/chest.110.6.1499","article-title":"Oral empiric treatment of community-acquired pneumonia: a multicenter, double-blind, randomized study comparing sparfloxacin with roxithromycin","volume":"110","author":"\u00d6rtqvist","year":"1996","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0088|cit88","first-page":"1322","article-title":"Assessment of the management of community-acquired pneumonia in adult outpatients","volume":"133","author":"Pavie","year":"2005","journal-title":"Revista M\u00e9dica de Chile"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1378\/chest.119.1.185","article-title":"Oral moxifloxacin vs high-dosage amoxicillin in the treatment of mild-to-moderate, community-acquired, suspected pneumococcal pneumonia in adults","volume":"119","author":"Petitpretz","year":"2001","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0090|cit90","first-page":"253","article-title":"Treatment of lower respiratory infections in outpatients with ofloxacin compared with erythromycin","volume":"17","author":"Peugeot","year":"1991","journal-title":"Drugs in Experimental and Clinical Research"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/resp.12013","article-title":"Systemic corticosteroids for community-acquired pneumonia: reasons for use and lack of benefit on outcome","volume":"18","author":"Polverino","year":"2013","journal-title":"Respirology"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1742-1241.2003.tb10511.x","article-title":"Efficacy and tolerability of once-daily oral therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults","volume":"57","author":"Pullman","year":"2003","journal-title":"Internation Journal of Clinical Practice"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ijantimicag.2004.01.011","article-title":"Azithromycin versus comparative therapy for the treatment of community acquired pneumonia","volume":"24","author":"Rahav","year":"2004","journal-title":"International Journal of Antimicrobial Agents"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0149-2918(00)88271-5","article-title":"Sparfloxacin vs clarithromycin in the treatment of community acquired pneumonia","volume":"21","author":"Ramirez","year":"1999","journal-title":"Clinical Therapeutics"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0095|cit95","first-page":"A3357","article-title":"Integrated safety summary of ceftaroline fosamil (cpt): safety in patients overall and for patients with community-acquired pneumonia (cap)","volume":"183","author":"Rank","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000239447","article-title":"Ofloxacin once daily versus twice daily in community-acquired pneumonia and acute exacerbation of chronic bronchitis","volume":"42","author":"Rayman","year":"1996","journal-title":"Chemotherapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002109.pub4-BIB0097|cit97","first-page":"49","article-title":"Phase III double-blind comparative study of sitafloxacin versus tosufloxacin in patients with community-acquired pneumonia","volume":"56","author":"Saito","year":"2008","journal-title":"Japanese Journal of Chemotherapy"},{"issue":"Suppl B","key":"10.1002\/14651858.CD002109.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/41.suppl_2.75","article-title":"Comparison of roxithromycin with cefixime in the treatment of adults with community-acquired pneumonia","volume":"41","author":"Salvarezza","year":"1998","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archinte.1988.00380020087014","article-title":"Blinded comparison of cefuroxime to cefaclor for lower respiratory tract infections","volume":"148","author":"Schleupner","year":"1988","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2169\/internalmedicine.48.1614","article-title":"A clinical comparative study of piperacillin and sulbactam\/ampicillin in patients with community-acquired bacterial pneumonia","volume":"48","author":"Seki","year":"2009","journal-title":"Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.diagmicrobio.2012.12.002","article-title":"Assessment of ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia due to Streptococcus pneumoniae: insights from two randomized trials","volume":"75","author":"Shorr","year":"2013","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jac\/dki480","article-title":"Efficacy and safety of twice-daily pharmacokinetically enhanced amoxicillin\/clavulanate (2000\/125 mg) in the treatment of adults with community-acquired pneumonia in a country with a high prevalence of penicillin-resistant Streptococcus pneumoniae","volume":"57","author":"Siquier","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1469-0691.2012.03838.x","article-title":"Macrolides vs. quinolones for community-acquired pneumonia: meta-analysis of randomized controlled trials","volume":"19","author":"Skalsky","year":"2013","journal-title":"Clinical Microbiology and Infection"},{"issue":"9","key":"10.1002\/14651858.CD002109.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11606-013-2400-x","article-title":"Cost-effectiveness of procalcitonin-guided antibiotic use in community acquired pneumonia","volume":"28","author":"Smith","year":"2013","journal-title":"Journal of General Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00044011-200929040-00005","article-title":"Generic versus non-generic formulation of extended-release clarithromycin in patients with community-acquired respiratory tract infections: a prospective, randomized, comparative, investigator-blind, multicentre study","volume":"29","author":"Snyman","year":"2009","journal-title":"Clinical Drug Investigation"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0149-2918(02)85136-0","article-title":"A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia","volume":"24","author":"Sokol","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1179\/joc.2004.16.1.102","article-title":"Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults","volume":"16","author":"Sopena","year":"2004","journal-title":"Journal of Chemotherapy"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0108|cit108","first-page":"87","article-title":"Ceftriaxon i. v.\/ efetametpivoxil versus efuroxim i. v.\/ efuroximatxetil","volume":"9","author":"Stille","year":"2000","journal-title":"Chemotherapie Journal"},{"issue":"94","key":"10.1002\/14651858.CD002109.pub4-BIB0109|cit109","first-page":"374","article-title":"A single-dose study to evaluate the pharmacokinetics, safety and tolerability of multiple formulations of PTK0796 in healthy subjects","volume":"18","author":"Sun","year":"2012","journal-title":"Clinical Microbiology and Infection"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/jac\/dkh356","article-title":"Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia","volume":"54","author":"Tellier","year":"2004","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0732-8893(92)90135-G","article-title":"A randomized double-blind controlled trial of roxithromycin and cefaclor in the treatment of acute lower respiratory tract infections in general practice","volume":"15","author":"Tilyard","year":"1992","journal-title":"Diagnostic Microbiology and Infectious Disease"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1183\/09031936.03.00045202","article-title":"Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia","volume":"21","author":"Torres","year":"2003","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD002109.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/BF01691581","article-title":"Trovafloxacin versus high-dose amoxicillin (1 g three times daily) in the treatment of community-acquired bacterial pneumonia","volume":"17","author":"Tr\u00e9moli\u00e8res","year":"1998","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"issue":"8-9","key":"10.1002\/14651858.CD002109.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.patbio.2005.07.010","article-title":"Efficacy and safety of pristinamycin vs amoxicillin in community acquired pneumonia in adults","volume":"53","author":"Tr\u00e9moli\u00e8res","year":"2005","journal-title":"Pathologie-Biologie"},{"issue":"11","key":"10.1002\/14651858.CD002109.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0149-2918(02)80083-2","article-title":"Cefditoren pivoxil versus cefpodoxime proxetil for community-acquired pneumonia: results of a multicenter, prospective, randomized, double-blind study","volume":"24","author":"Zyl","year":"2002","journal-title":"Clinical Therapeutics"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/MCP.0b013e32835f1c0b","article-title":"Advances in antibiotic therapy for community acquired pneumonia","volume":"19","author":"Viasusa","year":"2013","journal-title":"Current Opinion in Pulmonary Medicine"},{"issue":"10","key":"10.1002\/14651858.CD002109.pub4-BIB0117|cit117","first-page":"1032","article-title":"Postdated versus usual delayed antibiotic prescriptions in primary care: reduction in antibiotic use for acute respiratory infections","volume":"56","author":"Worrall","year":"2010","journal-title":"Canadian Family Physician"},{"issue":"11","key":"10.1002\/14651858.CD002109.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1164\/rccm.201007-1167OC","article-title":"Recombinant tissue factor pathway inhibitor in severe community-acquired pneumonia: a randomized trial","volume":"183","author":"Wunderink","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10156-013-0552-6","article-title":"Prospective randomized comparison study of piperacillin\/tazobactam and meropenem for healthcare-associated pneumonia in Japan","volume":"19","author":"Yamamoto","year":"2013","journal-title":"Journal of Infection and Chemotherapy (Official Journal of the Japan Society of Chemotherapy)"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1179\/1973947812Y.0000000028","article-title":"Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials","volume":"24","author":"Yuan","year":"2012","journal-title":"Journal of Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0121|cit121","first-page":"275","article-title":"Procalcitonin-guided algorithms of antibiotic therapy in community-acquired lower respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials","volume":"35","author":"Zhang","year":"2010","journal-title":"Chinese Journal of Tuberculosis and Respiratory Diseases"},{"issue":"Suppl E","key":"10.1002\/14651858.CD002109.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/jac\/26.suppl_E.71","article-title":"Efficacy and tolerance of cefpodoxime proxetil compared with ceftriaxone in vulnerable patients with bronchopneumonia","volume":"26","author":"Zuck","year":"1990","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0123|cit123","first-page":"340","article-title":"Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia","volume":"37","author":"Grupo de trabajo de la Asociaci\u00f3n Latinoamericana del T\u00f3rax","year":"2001","journal-title":"Archivos de Bronconeumolog\u00eda"},{"issue":"8","key":"10.1002\/14651858.CD002109.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S1579-2129(06)60322-4","article-title":"Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia","volume":"40","author":"Grupo de trabajo de la Asociaci\u00f3n Latinoamericana del T\u00f3rax","year":"2004","journal-title":"Archivos de Bronconeumolog\u00eda"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0125|cit125","volume-title":"Statistical Methods in Medical Research","author":"Armitage","year":"1994"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1164\/ajrccm.163.7.at1010","article-title":"Guidelines for the management of adults with community-acquired pneumonia","volume":"163","author":"American Thoracic Society","year":"2001","journal-title":"American Journal of Critical Care"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/thx.2004.024992","article-title":"2004 update of BTS pneumonia guidelines: what's new?","volume":"59","author":"Macfarlane","year":"2004","journal-title":"Thorax"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002109.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"iii1","DOI":"10.1136\/thx.2009.121434","article-title":"BTS guidelines for the management of community acquired pneumonia in adults: update 2009","volume":"64","author":"Lim","year":"2009","journal-title":"Thorax"},{"issue":"3","key":"10.1002\/14651858.CD002109.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-142-3-200502010-00006","article-title":"Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients","volume":"142","author":"Carratal\u00e0","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1086\/313959","article-title":"Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society","volume":"31","author":"Canadian Community-Acquired Pneumonia Working Group","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jama.1979.03290290021018","article-title":"Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975","volume":"241","author":"Foy","year":"1979","journal-title":"JAMA"},{"issue":"11-2","key":"10.1002\/14651858.CD002109.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/00365540500264050","article-title":"Swedish guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Hedlund","year":"2005","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0133|cit133","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1055\/s-0029-1243910","article-title":"Guidelines of the Paul-Ehrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the Management of Lower Respiratory Tract Infections and Community Acquired Pneumonia: Summary of the Update 2009","volume":"64","author":"H\u00f6ffken","year":"2010","journal-title":"Pneumologie"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/313954","article-title":"Practice guidelines for the management of community-acquired pneumonia in adults","volume":"31","author":"Infectious Diseases Society of America","year":"2000","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1086\/380488","article-title":"Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults","volume":"37","author":"Infectious Diseases Society of America","year":"2003","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002109.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/oxfordjournals.aje.a116770","article-title":"Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland","volume":"137","author":"Jokinen","year":"1993","journal-title":"American Journal of Epidemiology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002109.pub4-BIB0139|cit139","first-page":"79","article-title":"Guidelines for the management of community acquired pneumonia in adults, revised edition","volume":"11","author":"Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections","year":"2006","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0140|cit140","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org","author":"Lefebvre","year":"2011"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0141|cit141","article-title":"Community-acquired pneumonia","volume-title":"Clinical Evidence","volume":"8","author":"Loeb","year":"2002"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/thx.39.1.28","article-title":"Comparative radiographic features of community-acquired legionnaires' disease, pneumococcal pneumonia, mycoplasma pneumonia and psittacosis","volume":"39","author":"Macfarlane","year":"1984","journal-title":"Thorax"},{"issue":"5","key":"10.1002\/14651858.CD002109.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1183\/09031936.00109007","article-title":"Antibacterial class is not obviously important in outpatient pneumonia: a meta-analysis","volume":"31","author":"Maimon","year":"2008","journal-title":"European Respiratory Journal"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002109.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1086\/511159","article-title":"Infectious Diseases Society of America\/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults","volume":"44","author":"Mandell","year":"2007","journal-title":"Clinical Infectious Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002109.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/1120009X.2007.11782428","article-title":"Executive summary of the Gulf Cooperation Council practice guidelines for the management of community-acquired pneumonia","volume":"19","author":"Memish","year":"2007","journal-title":"Journal of Chemotherapy"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0146|cit146","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"1","key":"10.1002\/14651858.CD002109.pub4-BIB0147|cit147","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004418.pub3","article-title":"Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults","author":"Robenshtok","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD002109.pub4-BIB0148|cit148","first-page":"1296","article-title":"Management of community-acquired pneumonia in adults","volume":"97","author":"Working Group of the South African Thoracic Society","year":"2007","journal-title":"South African Medical Journal"},{"issue":"12","key":"10.1002\/14651858.CD002109.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"885","DOI":"10.3109\/00365548.2012.700120","article-title":"Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adults--Swedish Society of Infectious Diseases 2012","volume":"44","author":"Spindler","year":"2012","journal-title":"Scandinavian Journal of Infectious Diseases"},{"issue":"38","key":"10.1002\/14651858.CD002109.pub4-BIB0150|cit150","first-page":"2582","article-title":"Management of adult patients with community-acquired pneumonia. Evidence-based guidelines from the Swedish Infectious Diseases Association","volume":"105","author":"Str\u00e5lin","year":"2008","journal-title":"Lakartidningen"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1164\/ajrccm\/144.2.312","article-title":"Severe community-acquired pneumonia. Epidemiology and prognostic factors","volume":"144","author":"Torres","year":"1991","journal-title":"American Review of Respiratory Disease"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/thx.2009.129502","article-title":"Clinical and economic burden of community-acquired pneumonia among adults in Europe","volume":"67","author":"Welte","year":"2012","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0153|cit153","unstructured":"Wiersinga WJ Bonten MJ Boersma WG Jonkers RE Aleva RM Kullberg BJ Dutch guidelines on the management of community-acquired pneumonia in adults SWAB\/NVALT Guidelines Community-acquired Pneumonia 2011"},{"key":"10.1002\/14651858.CD002109.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0140-6736(87)90430-2","article-title":"Prospective study of the aetiology and outcome of pneumonia in the community","volume":"i","author":"Woodhead","year":"1987","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002109.pub4-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1469-0691.2011.03672.x","article-title":"Guidelines for the management of adult lower respiratory tract infections--full version","volume":"17","author":"Woodhead","year":"2011","journal-title":"Clinical Microbiology and Infection"},{"issue":"2","key":"10.1002\/14651858.CD002109.pub4-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002109.pub2","article-title":"Antibiotics for community acquired pneumonia in adult outpatients","author":"Bjerre","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD002109.pub4-BIB0157|cit157","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002109.pub3","article-title":"Antibiotics for community acquired pneumonia in adult outpatients","author":"Bjerre","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD002109.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T19:29:22Z","timestamp":1717442962000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002109.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Acute Respiratory Infections Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,10,9]]},"references-count":157,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2014,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002109.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,9]]}}}